FDA Postmarketing Requirements
What are FDA postmarketing requirements?
FDA postmarketing requirements (PMRs) are studies and clinical trials that a sponsor is required to run after approval under a statute or regulation. Postmarketing commitments (PMCs) are studies the sponsor has agreed to run but that no statute or regulation requires (FDA, PMRs and PMCs: Introduction). FDA's PMR/PMC database currently lists 2,535 open or tracked items for NDAs and BLAs, of which 2,038 are PMRs and 497 are PMCs.
Approach: I used FDA's PMR/PMC database (CDER and CBER), the current eCFR text of 21 CFR Part 314 and FDA's PMR/PMC introduction page. I did not pull the biologics rules in 21 CFR Part 601 or the PREA rule at 314.55; I cite those only as FDA's page lists them.
The legal bases for a PMR
FDA's page names four authorities that can make a study mandatory:
| Basis | What it requires | Items in the FDA database |
|---|---|---|
| FDAAA, FD&C Act 505(o)(3) | Studies to assess a known serious risk, a signal of a serious risk, or an unexpected serious risk | 1,123 PMRs |
| Pediatric Research Equity Act (PREA), 21 CFR 314.55(b) and 601.27(b) | Pediatric studies that were deferred at approval | 750 PMRs |
| Accelerated approval, 21 CFR 314.510 and 601.41 | Studies to confirm clinical benefit | 141 PMRs |
| Animal Rule, 21 CFR 314.610(b)(1) and 601.91(b)(1) | Studies of safety and clinical benefit once human studies are possible | 24 PMRs |
PMCs are recorded as type "506B PMC" (497 items).
What the regulations say:
- Accelerated approval: approval "will be subject to the requirement that the applicant study the drug further, to verify and describe its clinical benefit." Such studies must be adequate and well-controlled, and the applicant "shall carry out any such studies with due diligence" [1].
- Animal Rule: the applicant "must conduct postmarketing studies, such as field studies… when such studies are feasible and ethical." The application must also include a plan for these studies in case they later become feasible. FDA may additionally impose distribution restrictions and require patient labeling [2].
Examples from the database:
- 505(o)(3): a retrospective pregnancy-outcomes cohort study for Savella (milnacipran) [3], and a hepatic-impairment pharmacokinetic trial for Veppanu (vepdegestrant) [4].
- PREA: a deferred migraine study in patients aged 6-17 for Cambia. This one is Delayed; FDA denied the request to extend the deferral [5].
- Accelerated approval: a study to confirm the clinical benefit of ProAmatine (midodrine) [6].
- Animal Rule: a study to verify the clinical benefit and safety of Cyanokit [7].
- 506B PMC: a pediatric malignancy registry for Protopic [8].
Annual status reporting
For NDAs, 21 CFR 314.81(b)(2)(vii) requires a status report in the annual report for each postmarketing study on clinical safety, efficacy, clinical pharmacology or nonclinical toxicology. This covers studies FDA requires and studies the applicant committed to in writing. The status "shall be reported annually" until FDA agrees in writing that the study is fulfilled, no longer feasible, or would no longer provide useful information. Each report must include:
- a description of the study and its schedule (protocol, accrual, completion and final report dates);
- an explanation of the status, including enrolment numbers.
The regulation defines these status categories [9]:
- Pending: not yet started, but not yet late enough to count as delayed.
- Ongoing: on or ahead of the original schedule.
- Delayed: behind the original schedule.
- Terminated: ended early, with no final report submitted.
- Submitted: completed or terminated, with the final report submitted.
FDA "may publicly disclose" status information that identifies the applicant or establishes the study's status, including reasons for not conducting it. It does not disclose trade secrets or personal-privacy information [9].
The public database shows how the portfolio stands today:
| Status | Items |
|---|---|
| Delayed | 650 |
| Ongoing | 618 |
| Pending | 601 |
| Submitted | 282 |
| Fulfilled | 278 |
| Released | 98 |
| Terminated | 8 |
Separately, 314.81(b)(2)(viii) requires status reports for other postmarketing studies the applicant is running, including any agreed chemistry, manufacturing and controls (CMC) studies and all stability studies [9].
I can pull every PMR/PMC for a given product, applicant, or NDA/BLA number, or list all overdue (Delayed) items for a therapeutic area.
How do requirements differ from commitments?
The difference is legal force. A PMR is a study the sponsor is required to run under a statute or regulation. A PMC is a study the sponsor agreed to run that no statute or regulation requires (FDA, PMRs and PMCs: Introduction). Once agreed, both are reported and tracked in much the same way. The real differences are where the obligation comes from and what happens if you miss it.
Approach: I used FDA's PMR/PMC database (July 2026 edition), the current eCFR text of 21 CFR 314.81, and FDA's PMR/PMC introduction and FAQ pages. I did not pull the biologics reporting rules in 21 CFR Part 601.
Side by side
| Postmarketing requirement (PMR) | Postmarketing commitment (PMC) | |
|---|---|---|
| Where it comes from | A statute or regulation that lets FDA require it | The sponsor's agreement, usually in writing at approval |
| Legal bases | FD&C Act 505(o)(3) (FDAAA serious-risk studies); PREA deferred pediatric studies (21 CFR 314.55(b), 601.27(b)); accelerated approval confirmatory studies (21 CFR 314.510, 601.41); Animal Rule studies (21 CFR 314.610(b)(1), 601.91(b)(1)) | No statutory basis for requiring the study; FDA records them as "506B PMC" |
| Typical content | Safety studies, confirming clinical benefit, deferred pediatric work | Often extra pharmacology, dosing or diagnostic work, e.g. a pharmacokinetic study for Risvan [10], or a companion IVD validation for Jemperli [11] |
| Enforcement | Missing the annual report for a 505(o) study on time "will be considered a violation of FDCA section 505(o)(3)(E)(ii) and could result in enforcement action" (FDA FAQ) | The FAQ links no comparable violation to PMCs |
| Count in FDA's database | 2,038 | 497 |
What they have in common
- Annual status reports (NDAs). 21 CFR 314.81(b)(2)(vii) covers both kinds of study. It applies to each postmarketing study on clinical safety, efficacy, clinical pharmacology or nonclinical toxicology that is "required by FDA (e.g., accelerated approval clinical benefit studies, pediatric studies)" or that the applicant "has committed, in writing, to conduct." For either kind, status "shall be reported annually" until FDA agrees in writing that the study is fulfilled, no longer feasible, or would no longer give useful information [9].
- Deadline. Under section 506B, annual reports are due "within 60 days after the anniversary date of U.S. approval" (FDA FAQ).
- Same status terms. Both use Pending, Ongoing, Delayed, Terminated and Submitted [9]. FDA closes a study as either:
- Fulfilled: the final report is in and FDA is satisfied the terms were met.
- Released: FDA has relieved the applicant of the obligation.
- Public disclosure. FDA "may publicly disclose" status information for either. Trade secrets and personal-privacy information are protected [9]. Studies involving proprietary information, such as CMC studies, are left out of the public database. Those agreed CMC studies are reported separately under 314.81(b)(2)(viii) [9].
How the two portfolios compare
| Status | PMRs | PMCs |
|---|---|---|
| Delayed | 570 (28%) | 80 (16%) |
| Pending | 474 | 127 |
| Ongoing | 474 | 144 |
| Submitted | 220 | 62 |
| Fulfilled | 206 | 72 |
| Released | 87 | 11 |
| Terminated | 7 | 1 |
| Total | 2,038 | 497 |
The PMRs split by legal basis as follows: 505(o)(3) 1,123, PREA 750, accelerated approval 141, Animal Rule 24.
In the current FDA database, a larger share of PMRs (28%) than PMCs (16%) is Delayed. The database does not record why. One example of a PMR released before it finished is a juvenile-rodent neurobehavioral study for Singulair [12].
I can break this down by product, applicant or therapeutic area, for example every Delayed PMR versus PMC for one sponsor.
How can I check a study's status?
You check a study's status in FDA's public PMR/PMC database. FDA publishes it as a downloadable file, and the current edition is dated 31 July 2026. You can search it by product name, applicant, NDA/BLA number or the PMR/PMC identifier. Each entry gives the study's status, FDA's explanation of that status, the due date and the date of the sponsor's last annual status report. Name a product, sponsor or application number and I can look it up.
Approach: I searched FDA's PMR/PMC database (CDER and CBER, July 2026 edition) and pulled one record to show what an entry contains. The public database leaves out studies that involve proprietary information, such as agreed CMC studies.
What a status record shows
Here is the Cambia (diclofenac potassium) record from the last answer as an example [5]:
| Field | Value |
|---|---|
| Application | NDA 22165, approved 17 June 2009; applicant Cosette Pharmaceuticals Inc |
| Identifier and type | PMR 974-7, Pediatric Research Equity Act |
| Study | Deferred controlled safety and efficacy study for acute migraine in patients aged 6-17, with a PK run-in phase and a 12-month open-label safety extension |
| Status | Delayed |
| Status explanation | "Deferral Extension Requested 12/07/2022. Denied per FDA letter dated 01/23/2023. The Final Protocol, Study Completion, and Final Report Submission milestones were missed. Per the applicant s Annual Status Report, the study is pending initiation of subject enrollment." |
| Due date | 31 December 2021 |
| Last annual status report | 29 July 2025 |
Ways to find a study
- By product or applicant, for example "Cambia" or "Cosette".
- By application number, for example NDA 22165 or a BLA number.
- By PMR/PMC identifier, for example 974-7. One identifier can appear on more than one row, because a requirement can span several submissions.
- By filter: PMR or PMC, legal basis (505(o)(3), PREA, accelerated approval, Animal Rule, 506B PMC), status (Delayed, Ongoing, Pending, Submitted, Fulfilled, Released, Terminated), and centre (CDER or CBER).
Points to keep in mind
- The status comes from the sponsor's annual report. For NDAs, 21 CFR 314.81(b)(2)(vii) says the status "shall be reported annually" until FDA agrees in writing that the study is fulfilled, no longer feasible, or would no longer give useful information [9].
- Check how recent the report is. Look at the last annual status date next to the status. In the example, the newest report on file is from July 2025.
- Read the explanation field. It often holds the detail that matters: denied deferral extensions, missed milestones, or the reason a study was Released.
I can pull every PMR/PMC for one product, sponsor or application, or list all Delayed items with their explanations.